Serum myeloperoxidase: a novel biomarker for evaluation of patients with acute coronary syndrome
Heart Asia · 2009
DOI: 10.1136/ha.2009.000778 ↗Kurz gefasst
Fachartikel in der Zeitschrift Heart Asia, 2009. Verfasst von P Gururajan und 6 weiteren Autor:innen. Beteiligte Einrichtung: International Centre for Cardiothoracic and Vascular Diseases, Department of Biochemistry, Dr KM Cherian Heart Foundation (a unit of Frontier LifeLin…. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objectives Myeloperoxidase, an abundant leucocyte enzyme, is elevated in culprit lesions that have ruptured in patients with sudden cardiac injury. Multiple lines of evidence suggest an association between myeloperoxidase and inflammation and acute coronary syndrome. Myeloperoxidase has been proposed as a potent risk marker and diagnostic tool in acute coronary syndrome (ACS). Recent studies have reported the potential use of myeloperoxidase in acute coronary syndrome, but limited reports are available on its utility in different groups of ACS in the emergency department. Therefore the circulating levels of serum myeloperoxidase in patients with acute coronary syndrome and control subjects were studied. Design and setting The levels of serum myeloperoxidase were measured by ELISA in 485 patients admitted to emergency care unit, of which 89 patients were diagnosed as non-cardiac chest pain (NCCP). The levels of myeloperoxidase were significantly increased in patients with ACS when compared with controls and NCCP. From the receiver operator characteristic (ROC) curve analysis, the optimum value above which myeloperoxidase can be considered positive was found to be 48.02 U/ml. The area under the curve was found to be 0.956 with 95% CI (0.934 to 0.973) (p
Autor:innen und Institutionen
- International Centre for Cardiothoracic and Vascular Diseases, Department of Biochemistry, Dr KM Cherian Heart Foundation (a unit of Frontier LifeLine Pvt Ltd) Mogappair, Chennai, India.
- Department of Cardiology, Chettinad Hospital and Research Institute, Kelambakkam, India.
- International Centre for Cardiothoracic and Vascular Diseases, Department of Pathology, Dr KM Cherian Heart Foundation (a unit of Frontier LifeLine Pvt Ltd) Mogappair, Chennai, India.
- International Centre for Cardiothoracic and Vascular Diseases, Department of Cardiology, Dr KM Cherian Heart Foundation (a unit of Frontier LifeLine Pvt Ltd); Mogappair, Chennai, India.
Zitieren
APA
Gururajan, P., Gurumurthy, P., Nayar, P., Babu, S., Sarasabharati, A., Victor, D., & Cherian, K. M. (2009). Serum myeloperoxidase: a novel biomarker for evaluation of patients with acute coronary syndrome. Heart Asia. https://doi.org/10.1136/ha.2009.000778
Vancouver
Gururajan P, Gurumurthy P, Nayar P, Babu S, Sarasabharati A, Victor D, et al. Serum myeloperoxidase: a novel biomarker for evaluation of patients with acute coronary syndrome. Heart Asia. 2009. doi:10.1136/ha.2009.000778
BibTeX
@article{Gururajan2009,
author = {Gururajan, P and Gurumurthy, P and Nayar, P and Babu, S and Sarasabharati, A and Victor, D and Cherian, K M},
title = {Serum myeloperoxidase: a novel biomarker for evaluation of patients with acute coronary syndrome},
journal = {Heart Asia},
year = {2009},
doi = {10.1136/ha.2009.000778}
}
EUVIMED